Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Engineering × NET × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 39 Everolimus 33 Magnetic Resonance Spectroscopy 17 Temozolomide 15 lanreotide 13 gallium Ga 68 dotatate 13 Octreotide 13 Capecitabine 12 Nivolumab 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 cabozantinib 10 pembrolizumab 9 Specimen Handling 9 surufatinib 8 pasireotide 8 Sunitinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 amino-acid, glucose, and electrolyte solution 6 Lutetium-177 6 Fluorodeoxyglucose F18 6 Carboplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 Ipilimumab 5 Injections 5 Ga(III)-DOTATOC 5 Etoposide 5 Cisplatin 5 Bevacizumab 5 olaparib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡